Capricor Therapeutics, Inc.
CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscā¦ read more
Healthcare
Biotechnology
19 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.85
Price-8.12%
-$0.34
1Y
Price
Market Cap
$222.961m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-37.2%
3y CAGR+193.8%
5y CAGREarnings
-$114.594m
-9.1%
1y CAGR-83.4%
3y CAGR-56.8%
5y CAGREPS
-$2.32
-2.6%
1y CAGR-45.9%
3y CAGR-27.0%
5y CAGRBook Value
$278.703m
$326.284m
Assets$47.581m
Liabilities$21.125m
DebtDebt to Assets
6.5%
-
Debt to EBITDAFree Cash Flow
-$113.964m
-56.7%
1y CAGR-60.7%
3y CAGR-514.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company